VTGN

Vistagen Therapeutics, Inc. Common Stock

0.56

USD

VTGN Earnings Reports

Positive Surprise Ratio

VTGN beat 19 of 37 last estimates.

51%

Next Report

Date of Next Report

Feb 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

$373.32K

-$0.49

Implied change from Q2 26 (Revenue/ EPS)

+44.70%

-9.26%

Implied change from Q3 25 (Revenue/ EPS)

+59.54%

+6.52%

Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, VTGN reported earnings of -0.54 USD per share (EPS) for Q2 26, missing the estimate of -0.48 USD, resulting in a -11.23% surprise. Revenue reached 258.00 thousand, compared to an expected 248.20 thousand, with a 3.95% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 373.32 thousand USD, implying an decrease of -9.26% EPS, and increase of 44.70% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Regeneron Pharmaceuticals Inc

Report Date

Jan 30, 2026 For Q4 25

Estimate

$10.84

Actual

$11.44

Surprise

+5.52%

Nurix Therapeutics, Inc. Common stock

Report Date

Jan 28, 2026 For Q4 25

Estimate

-$0.88

Actual

-$0.82

Surprise

+7.66%

FAQ

What were Vistagen Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Vistagen Therapeutics, Inc. Common Stock reported EPS of -$0.54, missing estimates by -11.23%, and revenue of $258.00K, 3.95% above expectations.

How did the market react to Vistagen Therapeutics, Inc. Common Stock's Q2 2026 earnings?

The stock price moved -- 0%, changed from $3.80 before the earnings release to $3.80 the day after.

When is Vistagen Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Feb 11, 2026.

What are the forecasts for Vistagen Therapeutics, Inc. Common Stock's next earnings report?

Based on 7 analysts, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $373.32K for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.